STAT在皮肤病发病中作用的研究进展

基础医学与临床 ›› 2021, Vol. 41 ›› Issue (8): 1205-1209.

STAT在皮肤病发病中作用的研究进展

周琼艳¹, 林薇², 许素玲^1*, 赵可喻^1,3

宁波大学医学院附属医院 1.皮肤科; 2.药剂科,浙江宁波 315020;
3.宁波大学医学院,浙江宁波 315211

收稿日期:2020-08-17 修回日期:2021-04-15 出版日期:2021-08-05 发布日期:2021-07-21
通讯作者: *xusuling1210@126.com
基金资助:
浙江省实验动物科技计划项目(2018C37101);浙江省公益技术研究计划/实验动物项目(LGD19H110001);浙江省自然科学基金项目(LY18H110003);浙江省医药卫生重大科技计划项目(WKJ-ZJ-2012)

Research progress on the role of STAT in the pathogenesis of dermatosis

ZHOU Qiong-yan¹, LIN Wei², XU Su-ling^1*, ZHAO Ke-yu^1,3

1. Department of Dermatology; 2. Department of Pharmacy, the Affiliated Hospital of Medical School, Ningbo University, Ningbo 315020;
3. School of Medicine, Ningbo University, Ningbo 315211, China

Received:2020-08-17 Revised:2021-04-15 Online:2021-08-05 Published:2021-07-21
Contact: *xusuling1210@126.com

摘要/Abstract

摘要： 信号传导和转录激活因子(STAT)是有转录活性的蛋白,参与特应性皮炎、银屑病、皮肤肿瘤等多种皮肤病发病、皮损形成,与皮肤病严重程度相关,不同STAT在皮肤病中作用途径并不相同。STAT通过调控细胞信号传导,影响下游因子表达,发挥生物学效应,深入研究STAT表达水平及靶向基因,探讨其与皮肤病之间的关系,有助于发现皮肤病潜在的治疗靶点。

关键词: 信号传导和转录激活因子(STAT), 皮肤病, 通路

Abstract: Signal transducer and activator of transcription (STAT) proteins with transcriptional activity, which are involved in the pathogenesis and formation of skin lesions of atopic dermatitis, psoriasis, skin tumors and other dermatosis, and are related to the severity of dermatosis. Different STAT has different pathways in dermatosis. STAT regulate cell signal transduction, affect the expression of downstream factors, and exert biological effects. Further study of STAT expression level and targeted genes to explore the relationship between STAT and dermatosis will help to find potential therapeutic targets for dermatosis.

Key words: signal transducer and activator of transcription(STAT), dermatosis, pathway

中图分类号:

R751

周琼艳, 林薇, 许素玲, 赵可喻. STAT在皮肤病发病中作用的研究进展[J]. 基础医学与临床, 2021, 41(8): 1205-1209.

ZHOU Qiong-yan, LIN Wei, XU Su-ling, ZHAO Ke-yu. Research progress on the role of STAT in the pathogenesis of dermatosis[J]. Basic & Clinical Medicine, 2021, 41(8): 1205-1209.

参考文献

[1]Alves de Medeiros AK, Speeckaert R, Desmet E,et al. JAK3 as an emerging target for topical treatment of inflammatory skin diseases[J]. PLoS One, 2016, 11: e0164080.doi:10.1371/journal.pone.0164080.
[2]Bergallo M, Accorinti M, Galliano I, et al. Expression of miRNA 155, FOXP3 and ROR gamma, in children with moderate and severe atopic dermatitis[J]. Giorn Ital Dermat V, 2020, 155: 168-172.
[3]Sung YY, Kim HK. Crocin ameliorates atopic dermatitis symptoms by down regulation of Th2 response via blocking of NF-κB/STAT6 signaling pathways in mice[J]. Nutrients, 2018, 10: 1625. doi:10.3390/nu10111625.
[4]Jin WY, Huang W, Chen LQ, et al. Topical application of JAK1/JAK2 inhibitor momelotinib exhibits significant anti-inflammatory responses in DNCB-induced atopic dermatitis model mice[J]. Int J Mol Sci, 2018, 19: 3793. doi:10.3390/ijms19123973.
[5]Lee DY, Hwang CJ, Choi JY, et al. Inhibitory effect of carnosol on phthalic anhydride-induced atopic dermatitis via inhibition of STAT3[J]. Biomol Ther, 2017, 25: 535-544.
[6]Choi DW, Jung SY, Shon DH, et al. Piperine ameliorates trimellitic anhydride-induced atopic dermatitis-like symptoms by suppressing Th2-mediated immune responses via inhibition of STAT6 phosphorylation[J]. Molecules, 2020, 25: 2186. doi:10.3390/molecules25092186.
[7]Parisi R, Iskandar IYK, Kontopantelis E, et al. National, regional, and worldwide epidemiology of psoriasis:systematic analysis and modelling study[J]. BMJ,2020, 369:m1590.doi:10.1136/bmj.m1590.
[8]Johansen C, Rittig AH, Mose M, et al. STAT2 is involved in the pathogenesis of psoriasis by promoting CXCL11 and CCL5 production by keratinocytes[J]. PLoS One, 2017, 12: e0176994.doi: 10.1371/journal.pone.0176994.
[9]Qin X, Chen C, Zhang Y, et al. Acitretin modulates HaCaT cells proliferation through STAT1- and STAT3-dependent signaling[J]. Saudi Pharm J, 2017, 25: 620-624.
[10]Kulling PM, Olson KC, Hamele CE, et al. Dysregulation of the IFN-γ-STAT1 signaling pathway in a cell line model of large granular lymphocyte leukemia[J]. PLoS One, 2018, 13: e0193429. doi: 10.1371/journal.pone.0193429.
[11]Crncˇec I, Modak M, Gordziel C, et al. STAT1 is a sex-specific tumor suppressor in colitis-associated colorectal cancer[J]. Mol Oncol, 2018, 12: 514-528.
[12]Hu X, Yuan L, Ma T. Mechanisms of JAK-STAT signal-ing pathway mediated by CXCL8 gene silencing on epithelial-mesenchymal transition of human cutaneous melanoma cells[J]. Oncol Lett, 2020, 20: 1973-1981.
[13]Zhou X, Yan T, Huang C,et al. Melanoma cell-secreted exosomal mir-155-5p induce proangiogenic switch of cancer-associated fibroblasts via SOCS1/JAK2/STAT3 signaling pathway[J]. J Exp Clin Cancer Res, 2018, 37: 242.doi:10.1186/s13046-018-0911-3.
[14]Sim GC, Wu S, Jin L, et al. Defective STAT1 activation associated with impaired IFN-γ production in NK and T lymphocytes from metastatic melanoma patients treated with IL-2[J]. Oncotarget, 2016, 7: 36074-36091.
[15]Morgan EL, Wasson CW, Hanson L, et al. STAT3 activation by E6 is essential for the differentiation-dependent HPV18 life cycle[J]. PLoS Pathog, 2018, 14: e1006975.doi:10.1371/journal.ppat.1006975.
[16]Juczynska K, Wozniacka A, Waszczykowska E, et al. Expression of the JAK/STAT signaling pathway in bullous pemphigoid and dermatitis herpetiformis[J]. Mediat Inflamm, 2017, 67:6419.doi:10.1155/2017/6716419.
[17]Dörner T, Tanaka Y, Petri MA, et al. Baricitinib-associated changes in global gene expression during a 24-week phase II clinical systemic lupus erythematosus trial implicates a mechanism of action through multiple immune-related pathways[J]. Lupus Sci Med, 2020, 7: e000424. doi:10.1136/lupus-2020-000424.
[18]Maeda K, Kosugi T, Sato W, et al. CD147/basigin limits lupus nephritis and Th17 cell differentiation in mice by inhibiting the interleukin-6/STAT-3 pathway[J]. Arthritis Rheumatol, 2015, 67: 2185-2195.
[19]Slight-Webb S, Guthridge JM, Chakravarty EF, et al. Mycophenolate mofetil reduces STAT3 phosphorylation in systemic lupus erythematosus patients[J]. JCI Insight, 2019, 4: e124575. doi:10.1172/jci.insight.124575.
[20]Park JS, Kim SM, Hwang SH, et al. Combinatory treatment using tacrolimus and a STAT3 inhibitor regulate Treg cells and plasma cells[J]. Int J Immunopath Ph, 2018, 32: 1-8.
[21]Yoshida N, He F, Kyttaris VC. T cell-specific STAT3 deficiency abrogates lupus nephritis[J]. Lupus, 2019, 28: 1468-1472.
[22]Conn KL, Wasson P, Mcfarlane S, et al. Novel role for protein inhibitor of activated STAT4 (PIAS4) in the restriction of Herpes Simplex Virus 1 by the cellular intrinsic antiviral immune response[J]. J Virol, 2016, 90: 4807-4826.